Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Inclusion Criteria: * A signed and dated informed consent form (ICF) before any study-specific screening procedure was performed, * Male or female subjects aged 18 to 45 years, inclusive, * Body mass index (BMI) between 19 and 30 kg/m2, * Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead electrocardiogram (ECG), * Negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies and anti-human immunodeficiency virus (HIV) antibodies at screening, * Clinical laboratory test results clinically acceptable at screening and on D-1 of each treatment period, * Negative screen for alcohol and drugs of abuse at screening and on D-1 of each treatment period, * Non-smokers or ex-smokers for at least 3 months, * Volunteer able to participate, and willing to give written informed consent and comply with the study restrictions, If female: * Was not of childbearing potential by reason of surgery or, if of childbearing potential, uses an effective non-hormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap \[diaphragm or cervical or vault caps\] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he was the sole partner of that subject) for the entire duration of the study, * Negative serum pregnancy test at screening and a negative urine pregnancy test on D-1 of each treatment period. Exclusion Criteria: * Any clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders, or had a clinically relevant surgical history, * Any clinically relevant abnormality in the coagulation tests, * Any clinically relevant abnormality in the liver function tests, * History of relevant atopy or drug hypersensitivity, * History of alcoholism and/or drug abuse, * Current consumption of more than 14 units of alcohol per week \[1 unit of alcohol = 280 mL beer (3-4°) = 100 mL wine (10-12°) = 30 mL spirits (40°)\], * Any significant infection or known inflammatory process on screening or admission to each treatment period, * Any acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period, * Use of medicines within 2 weeks of admission to first period that could affect the subject's safety or other study assessments, in the investigator's opinion, * Previously received opicapone, * Involvement in other clinical trials of any type within 90 days prior to screening, * Participation in more than 2 clinical trials within the 12 months prior to screening, * Blood donation or received any blood transfusion or any blood products within the 3 months prior to screening, * Vegetarian, vegan or had medical dietary restrictions, * Subject not able to communicate reliably with the investigator, * Subjects who were unlikely to co-operate with the requirements of the study, * Subjects who were unwilling or unable to give written informed consent, If female: * Pregnant or breast-feeding, * If of childbearing potential, a positive serum pregnancy test, * Volunteer who did not use an accepted effective contraceptive method or used oral contraceptives,